Helius Medical Technologies - Home


Call us: +1 877-564-0008

Stock Quote - HSDT

*Delayed quote courtesy of Google.

Management Team

President and CEO

Mr. Andreeff is the General Partner and Portfolio Manager of Maple Leaf Partners, L.P. and the President of Andreeff Equity Advisors, L.L.C. Mr. Andreeff has managed investment portfolios since 1996 for Andreeff Equity, L.P., Andreeff Overseas Ltd. and Clover Partners, LP. Prior to managing portfolios, Mr. Andreeff worked as an associate analyst at Furman Selz and Granite Capital International Group. Currently, Mr. Andreeff serves as a Director of TraceSecurity Inc., HDL Therapeutics, Inc. and Myocardial Solutions, Ltd.

Mr. Andreeff received his Master's degree in Economics from the University of Texas at Arlington in 1991 and Bachelor's degree in Economics from the University of Texas at Arlington in 1989.

Chief Financial Officer

Jeff is an accomplished senior executive and director of public and privately held companies with broad experience in the biopharmaceutical, medical device, semiconductor capital equipment and water filtration markets. Mr. Mathiesen has served as Director and Audit Committee Chair of Panbela Therapeutics, Inc. (Nasdaq: PBLA), a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, since 2015, and was appointed Vice Chair and Lead Independent Director in March 2020. Mr. Mathiesen has also served as Director and Audit Committee Chair of NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a publicly traded medical technology company providing neuromodulation continuous EEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders, since 2017, and Healthcare Triangle, Inc. (Nasdaq: HCTI), a leading provider of cloud and digital transformation, managed services and data analytics platform for healthcare and life sciences industry, since April 2022. He previously served as Director and Audit Committee Chair for eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine, from 2018 to 2020. Mr. Mathiesen previously served as the CFO of Gemphire Therapeutics Inc., a publicly-held clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic disorders, and as CFO of Sunshine Heart, Inc., a publicly-held early-stage medical device company, both of which completed successful IPOs and follow-on equity offerings. Mr. Mathiesen has held executive and financial management positions with private and publicly traded companies dating back to 1987. He began his career at Deloitte & Touche LLP. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.

Chief Medical Officer

A rare disease expert and a pioneer in the field of applied theranostic for the development of disease-modifying treatments. Board-certified Neurologist, she holds a PhD in Pharmacology and presents with more than 20 years of drug development expertise in the pharmaceutical industry and academia. She started her clinical practice activity in 1994 with specialist clinics in Europe where continues her involvement as a specialist consultant managing patients with movement disorders and rare neuromuscular disorders.

Currently serving as Chief Medical Officer at Helius Medical Technologies, she performed, until March 2021, as Head US Medical Strategy for Neurology at Lundbeck and, previously in 2017, as Head of Medical Affairs at Luitpold. In 2013, she founded Synaerion Therapeutics and its affiliate Thera Neuropharma, Inc. (2016), two privately-held biotechnology companies developing a small molecule regenerative therapy and RNAi-based integrated technology platform for ALS and traumatic brain injury (“TBI”), where she oversaw all aspects of the companies’ management and strategy as Chief Executive Officer, President & Chairwoman of the Board from 2014 to 2017 and continues to serve as President & Chairwoman. In 2009, she founded StratMedica, LLC, a privately-held company designed to provide corporate clients with contract senior management support and directed, as Principal from 2009 to 2016, clinical development and medical programs for several healthcare companies, including Johnson & Johnson and Teva. She started her pharmaceutical career in 2001 as Global Clinical Development Lead at GE Healthcare (formerly Amersham Health), then as Director of Medical Strategy at Bristol-Myers Squibb in 2005 and, in 2007, as Senior Director and Global Medical Lead at Shire Pharmaceuticals.

Senior Vice President, Engineering, Quality & Regulatory Affairs

Larry’s medical device industry experience spans leadership responsibilities in regulatory, quality, engineering and clinical. He has worked in large organizations such as Johnson and Johnson, Philips, St. Jude, and in start-up companies; this experience spans established medical device technologies as well as new novel technologies including AI. Larry has been with Helius Medical, Inc since late 2018 and serves as the Senior Vice President of Product Development, Regulatory Affairs, and Quality. Within these roles he has helped attain PoNS US FDA breakthrough device designations in MS and Stroke, US de novo classification in MS, along with marketing authorizations in Canada and Australia. Larry holds a BS in electrical engineering from Rutgers, a Masters in Engineering Science and an MBA from Penn State.